C. Slabber

508 total citations
20 papers, 367 citations indexed

About

C. Slabber is a scholar working on Surgery, Cancer Research and Oncology. According to data from OpenAlex, C. Slabber has authored 20 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 7 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in C. Slabber's work include Ovarian cancer diagnosis and treatment (5 papers), Lung Cancer Treatments and Mutations (3 papers) and Cancer, Lipids, and Metabolism (3 papers). C. Slabber is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Lung Cancer Treatments and Mutations (3 papers) and Cancer, Lipids, and Metabolism (3 papers). C. Slabber collaborates with scholars based in South Africa, Switzerland and United States. C. Slabber's co-authors include Geoffrey Falkson, M. Biakhov, A. Garin, Meinolf Karthaus, Albrecht Kretzschmar, David Irwin, G. Steger, H. Kröning, Norbert Marschner and C. Giorgetti and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

C. Slabber

18 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Slabber South Africa	8	134	129	119	113	76	20	367
Lorenzo Gervaso Italy	10	202 1.5×	57 0.4×	43 0.4×	110 1.0×	41 0.5×	46	447
Ilias Athanasiadis Greece	10	48 0.4×	173 1.3×	41 0.3×	164 1.5×	51 0.7×	37	416
José Leonidas Alves Brazil	7	149 1.1×	34 0.3×	31 0.3×	137 1.2×	18 0.2×	15	317
Lisa Y. Law United States	8	44 0.3×	55 0.4×	22 0.2×	49 0.4×	26 0.3×	21	279
Ankie Kleinjan Netherlands	6	245 1.8×	51 0.4×	89 0.7×	25 0.2×	53 0.7×	9	305
J.-L. Houpeau France	7	18 0.1×	80 0.6×	89 0.7×	63 0.6×	8 0.1×	8	271
Vikash Jain India	10	20 0.1×	95 0.7×	19 0.2×	109 1.0×	76 1.0×	19	296
Andrew Aw Canada	9	59 0.4×	17 0.1×	79 0.7×	71 0.6×	37 0.5×	21	272
Jwa Hoon Kim South Korea	11	30 0.2×	81 0.6×	17 0.1×	112 1.0×	44 0.6×	30	348
L.T. Vlasveld Netherlands	11	22 0.2×	65 0.5×	34 0.3×	81 0.7×	22 0.3×	16	295

Countries citing papers authored by C. Slabber

Since Specialization

Citations

This map shows the geographic impact of C. Slabber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Slabber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Slabber more than expected).

Fields of papers citing papers by C. Slabber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Slabber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Slabber. The network helps show where C. Slabber may publish in the future.

Co-authorship network of co-authors of C. Slabber

This figure shows the co-authorship network connecting the top 25 collaborators of C. Slabber. A scholar is included among the top collaborators of C. Slabber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Slabber. C. Slabber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Slabber, C. & Jan S. Tchorz. (2025). Starvation induces metabolic hepatocyte reprogramming. Nature Metabolism. 7(5). 864–866.

2.

Slabber, C., Luigi Tortola, Chiu‐Yin Kwan, et al.. (2025). An Nrf2-NF-κB Crosstalk Controls Hepatocyte Proliferation in the Normal and Injured Liver. Cellular and Molecular Gastroenterology and Hepatology. 19(7). 101480–101480. 1 indexed citations

3.

Slabber, C., Tobias Speicher, Susagna Padrissa‐Altés, et al.. (2023). The ubiquitin ligase Uhrf2 is a master regulator of cholesterol biosynthesis and is essential for liver regeneration. Science Signaling. 16(787). eade8029–eade8029. 5 indexed citations

4.

Slabber, C., Luigi Tortola, Lea Pohlmeier, et al.. (2021). Fibroblast growth factor receptor 3 in hepatocytes protects from toxin-induced liver injury and fibrosis. iScience. 24(10). 103143–103143. 10 indexed citations

5.

Bär, Dominik, et al.. (2017). The RNA helicase DHX 9 establishes nucleolar heterochromatin, and this activity is required for embryonic stem cell differentiation. EMBO Reports. 18(7). 1248–1262. 38 indexed citations

6.

Cinieri, Saverio, Arlene Chan, Kadri Altundağ, et al.. (2014). Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial).. Journal of Clinical Oncology. 32(15_suppl). 1044–1044. 3 indexed citations

7.

Falkson, Carla I., et al.. (2011). Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group.. PubMed. 4(1). 9–14. 3 indexed citations

8.

Rapoport, Bernardo L., et al.. (2009). Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer. International Journal of Gynecological Cancer. 19(6). 1137–1141. 21 indexed citations

9.

Kyle, Robert A., Susanna Jacobus, William R. Friedenberg, et al.. (2009). The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high‐dose cyclophosphamide and α₂β interferon versus VBMCP. Cancer. 115(10). 2155–2164. 8 indexed citations

10.

Vorobiof, Daniel, et al.. (2008). Phase II study of first line combination therapy with pegylated liposomal doxorubicin (PLD) and carboplatin in patients (pts) with extensive disease small cell lung cancer(ED SCLC). Journal of Clinical Oncology. 26(15_suppl). 19089–19089. 1 indexed citations

11.

Rapoport, Bernardo L., et al.. (2008). Phase II study of combination therapy with pegylated liposomal doxorubicin (PLD)and carboplatin in patients (pts) with relapsed, platinum sensitive and platinum semi-sensitive ovarian cancer. Journal of Clinical Oncology. 26(15_suppl). 5555–5555. 2 indexed citations

12.

Karthaus, Meinolf, Albrecht Kretzschmar, H. Kröning, et al.. (2005). Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Annals of Oncology. 17(2). 289–296. 159 indexed citations

13.

Rapoport, Bernardo L., C. Slabber, Graham Cohen, et al.. (2005). Phase II study of combination therapy with CHOP Interferon (IFN) alpha and rituximab (R) in chemo-naive patients (pts) with diffuse large B cell non-Hodgkin’s lymphoma (NHL). Journal of Clinical Oncology. 23(16_suppl). 6694–6694. 1 indexed citations

14.

Vorobiof, Daniel, et al.. (2004). First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer: a multicentre phase II study. The Breast. 13(3). 219–226. 35 indexed citations

15.

Vorobiof, Daniel, Bernardo L. Rapoport, C. Slabber, et al.. (2004). Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology. 22(14_suppl). 5091–5091. 3 indexed citations

16.

Vorobiof, Daniel, Bernardo L. Rapoport, C. Slabber, et al.. (2004). Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology. 22(14_suppl). 5091–5091. 6 indexed citations

17.

Vorobiof, D.A., Bernardo L. Rapoport, André Uys, et al.. (2003). 179 A phase II second line study of liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancer with a disease free interval equal or greater than 6 months. European Journal of Cancer Supplements. 1(5). S57–S57. 1 indexed citations

18.

Slabber, C., et al.. (1998). A Randomized Study of Radiotherapy Alone Versus Radiotherapy Plus 5-Fluorouracil and Platinum in Patients With Inoperable, Locally Advanced Squamous Cancer of the Esophagus. American Journal of Clinical Oncology. 21(5). 462–465. 54 indexed citations

19.

Slabber, C., et al.. (1996). 13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: A phase II trial. Investigational New Drugs. 14(4). 391–394. 16 indexed citations

20.

Slabber, C.. (1977). Afrikaans as a medium of communication in medicine.. PubMed. 52(7). 256–7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact